Recommendations for Comprehensive Stroke Centers
A Consensus Statement From the Brain Attack Coalition

Mark J. Alberts, MD; Richard E. Latchaw, MD; Warren R. Selman, MD; Timothy Shephard, RN; Mark N. Hadley, MD; Lawrence M. Brass, MD; Walter Koroshetz, MD; John R. Marler, MD; John Booss, MD; Richard D. Zorowitz, MD; Janet B. Croft, PhD; Ellen Magnis, MBA; Diane Mulligan; Andrew Jagoda, MD; Robert O’Connor, MD; C. Michael Cawley, MD; J.J. Connors, MD; Jean A. Rose-DeRenzy, CN, RN; Marian Emr; Margo Warren; Michael D. Walker, MD; for the Brain Attack Coalition

Background and Purpose—To develop recommendations for the establishment of comprehensive stroke centers capable of delivering the full spectrum of care to seriously ill patients with stroke and cerebrovascular disease. Recommendations were developed by members of the Brain Attack Coalition (BAC), which is a multidisciplinary group of members from major professional organizations involved with the care of patients with stroke and cerebrovascular disease.

Summary of Review—A comprehensive literature search was conducted from 1966 through December 2004 using Medline and Pub Med. Articles with information about clinical trials, meta-analyses, care guidelines, scientific guidelines, and other relevant clinical and research reports were examined and graded using established evidence-based medicine approaches for therapeutic and diagnostic modalities. Evidence was also obtained from a questionnaire survey sent to leaders in cerebrovascular disease. Members of BAC reviewed literature related to their field and graded the scientific evidence on the various diagnostic and treatment modalities for stroke. Input was obtained from the organizations represented by BAC. BAC met on several occasions to review each specific recommendation and reach a consensus about its importance in light of other medical, logistical, and financial factors.

Conclusions—There are a number of key areas supported by evidence-based medicine that are important for a comprehensive stroke center and its ability to deliver the wide variety of specialized care needed by patients with serious cerebrovascular disease. These areas include: (1) health care personnel with specific expertise in a number of disciplines, including neurosurgery and vascular neurology; (2) advanced neuroimaging capabilities such as MRI and various types of cerebral angiography; (3) surgical and endovascular techniques, including clipping and coiling of intracranial aneurysms, carotid endarterectomy, and intra-arterial thrombolytic therapy; and (4) other specific infrastructure and programmatic elements such as an intensive care unit and a stroke registry. Integration of these elements into a coordinated hospital-based program or system is likely to improve outcomes of patients with strokes and complex cerebrovascular disease who require the services of a comprehensive stroke center.

Key Words: cerebrovascular disorders ■ cerebral hemorrhage ■ healthcare systems ■ patient care ■ university medical centers

Stroke is a common and serious disorder. Each year, ≈750 000 individuals have a new or recurrent stroke in the United States.1 Hospitalizations attributable to stroke appear to be increasing, with 822 000 per year in 1997 compared with 593 000 per year in 1988.2 These figures suggest that the care of patients hospitalized because of a stroke will continue to be a significant health care issue into the foreseeable future.

In 2000, the Brain Attack Coalition (BAC) discussed the concept of stroke centers and proposed 2 types of centers:
primary and comprehensive. A primary stroke center (PSC) has the necessary staffing, infrastructure, and programs to stabilize and treat most acute stroke patients. Details about specific elements of a PSC have been published previously. Efforts are now under way to credential facilities as PSCs. Several dozen hospitals have either been certified as PSCs or are going through a certification process. Although PSCs provide stroke patients with high-quality care, some patients with complex stroke types, severe deficits, or multiorgan disease may require and benefit from specialized care and technological resources not available in a typical PSC. Such patients often require advanced diagnostic and treatment procedures directed by specially trained physicians and other health care professionals.

A comprehensive stroke center (CSC) is defined as a facility or system with the necessary personnel, infrastructure, expertise, and programs to diagnose and treat stroke patients who require a high intensity of medical and surgical care, specialized tests, or interventional therapies. The types of patients who might use and benefit from a CSC include (but are not limited to) patients with large ischemic strokes or hemorrhagic strokes, those with strokes from unusual etiologies or requiring specialized testing or therapies, or those requiring multispecialty management. Additional functions of a CSC would be to act as a resource center for other facilities in their region, such as PSCs. This might include providing expertise about managing particular cases, offering guidance for triage of patients, making diagnostic tests or treatments available to patients treated initially at a PSC, and being an educational resource for other hospitals and health care professionals in a city or region. In an effort to provide guidance to health care professionals, hospitals, and administrators, BAC has established recommendations for the development of a CSC or system. The purposes of this article are to present the key components of a CSC or system and outline how each element of a CSC can be met and documented. These recommendations should be viewed with some flexibility so that individual facilities and health care systems may develop their own CSC criteria on the basis of these recommendations, yet modified to address and meet local practices and preferences. The designation of a PSC versus a CSC does not imply a difference in the quality of care, which is expected to be high at both types of centers. As this document is circulated and discussed, BAC anticipates further refinements and improvements that will meet the needs of patients, health care providers, hospitals, and health care systems.

**Methods**

Five processes were used for the development of the CSC recommendations: (1) a comprehensive literature review, (2) a questionnaire survey of stroke thought leaders, (3) input from the professional organizations represented by BAC, (4) grading of published medical evidence for treatments and diagnostic tests, and (5) group consensus of the BAC executive committee. The literature review was conducted using the Medline database and Pub Med from 1966 to December 2004. English language articles that focused on various tests, techniques, expertise, or programs related to the care of stroke patients were reviewed and evaluated. Meta-analyses, consensus statements, practice guidelines, and position articles were also reviewed. Some components such as personnel and staffing are not easily graded using evidence-based medicine protocols. In such cases, the other methods listed above were used to formulate recommendations.

Members of the executive committee of BAC were asked to query their parent organizations for guidance about the essential elements for a CSC. Their specific recommendations were considered for inclusion into this document. The questionnaire survey consisted of 40 questions dealing with various potential elements of a CSC. It was mailed to 160 stroke program directors and other physicians with interest and expertise in stroke care (ie, vascular neurosurgeons, neurologists, emergency department [ED] physicians). Respondents were asked to rank each element on a scale of 1 to 5 (least important to most important) in terms of importance for the care of stroke patients in a CSC and to indicate whether their hospital had each element. Where appropriate, standard evidence-based medicine assessment criteria were used to grade recommendations for various therapies used at a CSC (Table 1). For diagnostic testing, we evaluated the evidence using criteria developed recently for assessing the utility of cerebral perfusion techniques (with some modifications). Responses from the questionnaire cited above were used when appropriate. Finally, BAC executive committee members met on several occasions in person and via teleconference to review and refine the list of elements for a CSC and to develop suggestions for how each component could be documented.

**Results**

The key components of a CSC or system can be defined in 4 major areas: (1) personnel with specific areas of expertise, (2) specialized diagnostic and treatment techniques, (3) facility infrastructure, and (4) other programmatic areas (Table 2). These elements are best illustrated by the types of patients cared for in a CSC and the medical needs of those patients (Table 3). Results of the national survey are included in the appendix.

**Personnel and Clinical Expertise**

A CSC should have the following personnel: (1) a center director, (2) neurologists and neurosurgeons, (3) surgeons with expertise performing carotid endarterectomy (CEA), (4) diagnostic radiologists, (5) physicians with expertise in interventional endovascular neuroradiology procedures and techniques (6) ED personnel and links to emergency medical services (EMS), (7) radiology technologists, (8) nursing staff who are trained in the care of stroke patients, (9) advanced practice nurses (APNs), (10) physicians with expertise in critical care or neurointensive care, echocardiography, carotid ultrasound (U/S), and transcranial Doppler (TCD), (11) physicians and therapists with training in rehabilitation, and (11) case managers and social workers.

Strong leadership is an important element for the successful formation and operation of a CSC. The need for the CSC director to have a significant amount of training and expertise in vascular neurology or neurosurgery is supported by the questionnaire survey and BAC. The CSC director might be a neurologist or neurosurgeon, although other medical professionals could fulfill this role. Examples of qualifications for a CSC director include >2 of the following: (1) a board-certified neurologist or neurosurgeon who has completed a stroke fellowship or vascular neurosurgery fellowship or has equivalent experience, (2) board certified in vascular neurology, (3) a fellow of the Stroke Council of the American Heart Association (AHA) (4) a clinician who diagnoses and treats ≥50 patients with cerebrovascular disease annually; (5) a
TABLE 1. Approach to Grading Recommendations*

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Therapy/Treatment</th>
<th>Diagnostic Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Data from RCT with sufficient statistical power to make false positive/negative findings unlikely; treatment may be FDA-approved</td>
<td>Evidence from prospective study(s) in a broad spectrum of patients; gold standard comparisons when appropriate; high accuracy rate</td>
</tr>
<tr>
<td>II</td>
<td>Data from RCT, but may have false positives or negatives; may not be FDA-approved, but Rx is widely or commonly used in many medical centers</td>
<td>Evidence from prospective study of a narrow patient population or well-designed retrospective studies of a broad population; comparison with gold standard or other reasonable validated alternative test</td>
</tr>
<tr>
<td>III</td>
<td>Data from nonrandomized cohort studies; Rx is used in some settings but not widely adopted</td>
<td>Evidence from retrospective studies in a narrow patient population</td>
</tr>
<tr>
<td>IV</td>
<td>Data from nonrandomized studies using historical controls</td>
<td>Most evidence from case series or expert opinion panels</td>
</tr>
<tr>
<td>V</td>
<td>Data from anecdotal case series or several case reports</td>
<td>...</td>
</tr>
</tbody>
</table>

Strength of Recommendation

- Grade A: Supported by level I evidence
- Grade B: Supported by level II evidence
- Grade C: Supported by level III, IV, or V evidence
- Grade D: ... 

*In cases in which this type of grading is not directly applicable to a specific recommendation, the authors considered the body of available evidence and practice standards to determine the appropriate grading.

RCT indicates randomized controlled trial; Rx, therapy.

Although it is difficult to quantify the quality of nursing care, the consensus of BAC and other practitioners is that high-quality nursing care is a key factor in determining patient outcomes after a stroke. The majority of nurses caring for stroke patients in an ICU, stroke unit, and ward should be registered nurses. All nurses in a CSC should be familiar with standard neurologic assessments and scales, stroke protocols, care maps, ongoing research projects, and new patient care techniques related to stroke. Nurses caring primarily for stroke patients should attend training sessions sponsored by the CSC (ie, in services, seminars, specialized lectures) at least 3 times per year. Such nurses should participate in at least 10 hours of continuing education units (CEUs) activities (or other educational programs) annually that are related to or focused on cerebrovascular disease. Each nurse should have a file that documents his/her participation in the above activities. It is suggested that each CSC nurse (stroke unit or ICU) attend at least 1 national or regional meeting every other year that focuses on some aspect of cerebrovascular disease.

An APN is a vital team member involved in several important aspects of a CSC such as patient care, care maps, research activities, stroke registries, educational programs, and quality assurance. The designation of APN could include a nurse practitioner, master’s-prepared clinical nurse specialist, or American Board of Neuroscience Nurses-certified nurse. It is recommended that a CSC have at least 1 APN (or similar personnel) to implement and coordinate the programs outlined below. This recommendation is supported by BAC as well as the survey results.

It is vital that the CSC staff be fully integrated with EMS personnel and ED staff. EMS and ED personnel should be very familiar with the diagnosis and treatment of patients with cerebrovascular disease. Several studies have documented the importance of the EMS system and ED personnel for the rapid identification and transportation of stroke and
TABLE 2. Components of a CSC

<table>
<thead>
<tr>
<th>Recommendation (grade)</th>
<th>Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Personnel with expertise in the following areas</strong></td>
<td></td>
</tr>
<tr>
<td>Vascular neurology</td>
<td>Neuroscience intensive care</td>
</tr>
<tr>
<td>Vascular neurosurgery</td>
<td>Nursing director for stroke program</td>
</tr>
<tr>
<td>APN</td>
<td></td>
</tr>
<tr>
<td>Vascular surgery</td>
<td></td>
</tr>
<tr>
<td>Diagnostic radiology/neuroradiology</td>
<td></td>
</tr>
<tr>
<td>Interventional/endovascular physician(s)</td>
<td></td>
</tr>
<tr>
<td>Critical care medicine</td>
<td></td>
</tr>
<tr>
<td>Physical medicine and rehabilitation</td>
<td></td>
</tr>
<tr>
<td>Rehabilitation therapy (physical, occupational, speech therapy)</td>
<td></td>
</tr>
<tr>
<td>Staff stroke nurse(s)</td>
<td></td>
</tr>
<tr>
<td>RT</td>
<td></td>
</tr>
<tr>
<td>Swallowing assessment</td>
<td></td>
</tr>
<tr>
<td><strong>Diagnostic techniques</strong></td>
<td></td>
</tr>
<tr>
<td>MRI with diffusion (IA)</td>
<td>MR perfusion (IIB)</td>
</tr>
<tr>
<td>MRA/MRV (IA)</td>
<td>CT perfusion (IIIC)</td>
</tr>
<tr>
<td>CTA (IA)</td>
<td>Xenon CT (IIIC)</td>
</tr>
<tr>
<td>Digital cerebral angiography (IA)</td>
<td>SPECT (IIIC)</td>
</tr>
<tr>
<td>TCD (IA)</td>
<td>PET (IIB)</td>
</tr>
<tr>
<td>Carotid duplex U/S (IA)</td>
<td></td>
</tr>
<tr>
<td>Transesophageal echo (IA)</td>
<td></td>
</tr>
<tr>
<td><strong>Surgical and interventional therapies</strong></td>
<td></td>
</tr>
<tr>
<td>CEA (IA)</td>
<td></td>
</tr>
<tr>
<td>Clipping of intracranial aneurysm (IA)</td>
<td>Stenting/angioplasty of extracranial vessels (IIB)*</td>
</tr>
<tr>
<td>Placement of ventriculostomy (IA)</td>
<td>Stenting/angioplasty of intracranial vessels (IIIC)*</td>
</tr>
<tr>
<td>Hematoma removal/drainage (IIB–VC)</td>
<td></td>
</tr>
<tr>
<td>Placement of intracranial pressure transducer (VC)</td>
<td></td>
</tr>
<tr>
<td>Endovascular ablation of IAs/AVMs (IA)</td>
<td></td>
</tr>
<tr>
<td>IA reperfusion therapy (IIB)</td>
<td></td>
</tr>
<tr>
<td>Endovascular Rx of vasospasm (IIIC)</td>
<td></td>
</tr>
<tr>
<td><strong>Infrastructure</strong></td>
<td></td>
</tr>
<tr>
<td>Stroke unit† (IA)</td>
<td>Stroke clinic</td>
</tr>
<tr>
<td>ICU</td>
<td></td>
</tr>
<tr>
<td>Operating room staffed 24/7</td>
<td>Air ambulance</td>
</tr>
<tr>
<td>Interventional services coverage 24/7</td>
<td>Neuroscience ICU</td>
</tr>
<tr>
<td>Stroke registry (IIIC)</td>
<td></td>
</tr>
<tr>
<td><strong>Educational/research programs</strong></td>
<td></td>
</tr>
<tr>
<td>Community education (IA)</td>
<td>Clinical research</td>
</tr>
<tr>
<td>Community prevention (IA)</td>
<td>Laboratory research</td>
</tr>
<tr>
<td>Professional education</td>
<td>Fellowship program</td>
</tr>
<tr>
<td>Patient education</td>
<td>Presentations at national meetings</td>
</tr>
</tbody>
</table>

*Although these therapies are currently not supported by grade IA evidence, they may be useful for selected patients in some clinical settings. Therefore, a CSC that does not offer these therapies should have an established referral mechanism and protocol to send appropriate patients to another facility that does offer these therapies; †stroke unit may be part of an ICU.

Patients and the initiation of therapy.\textsuperscript{12–16} EMS and ED personnel should attend initial and ongoing educational programs (i.e., in services, CME programs, grand rounds) that focus on cerebrovascular disease. Ideally, the ED physicians should be board certified. They should meet with the CSC director at least semiannually and review care issues. Other aspects of the integration of the ED/EMS personnel with a stroke center are reviewed in the PSC recommendations.\textsuperscript{3}

Rehabilitation assessments and treatments (physical therapy, occupational therapy, and speech therapy) are an impor-
TABLE 3. Use of CSC Components in Various Patient Populations

<table>
<thead>
<tr>
<th>Personnel</th>
<th>Ischemic Stroke</th>
<th>ICH</th>
<th>SAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular neurologist</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Neurosurgeon</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Intensivist</td>
<td>As needed</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vascular surgeon</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endovascular specialist</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Care setting</td>
<td>Stroke unit</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>ICU</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td>MRI/MRA, DWI</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>MRV</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Digital angiography</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Carotid ultrasound</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TCD</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TEE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endovascular therapy</td>
<td>Aneurysm ablation</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AVM embolization</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Angioplasty for vasospasm</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stent/angioplasty for atherothrombosis</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reperfusion techniques</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>Venticulostomy</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Intracranial pressure transducer</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Hemicraniectomy</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hematoma removal</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Aneurysm clipping</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CEA</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain biopsy</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Diagnostic Imaging: Techniques and Personnel

Patients in a CSC need accurate imaging of the brain and related vasculature and physiological evaluation regarding the effects of cerebral ischemia and hemorrhage. Appropriate computed tomographic resources are a prerequisite for being a PSC, the recommendations for which are not repeated. This section details the recommendations for other imaging and related techniques.

MRI and Related Techniques

The contrast resolution of MRI is significantly higher than computed tomography (CT), making it far more sensitive than CT for detecting the often subtle abnormalities seen in early cerebral ischemia and other conditions. Numerous studies have clearly demonstrated the superiority of MRI for detecting acute ischemia (especially in the posterior fossa) as well as other processes that can present with stroke-like symptoms (grade IA). Basic MRI at a CSC must be available on a 24/7 basis, even if personnel are called in from home. An MRI should be completed within 2 hours of the test being ordered at a CSC.

Diffusion-weighted MRI (DWI) is very sensitive for detecting cerebral ischemia within minutes after its onset, far exceeding any other imaging method available today. Calculation of the apparent diffusion coefficient is important to confirm that a diffusion abnormality is attributable to ischemia. DWI detects >90% of acute ischemic lesions in the brain. Patterns of stroke seen with DWI may also provide important information about stroke mechanism.

Although results of DWI may not affect outcome, it is a valuable diagnostic tool and should be part of the evaluation of patients with an acute ischemic stroke (grade IA). DWI detects >90% of acute ischemic lesions in the brain. Patterns of stroke seen with DWI may also provide important information about stroke mechanism.

Magnetic resonance perfusion provides valuable information about blood flow in specific brain regions and vascular territories. It can be useful in determining the size of a perfusion deficit and identifying brain tissue that may be ischemic but not infarcted. MR perfusion defects may correlate with clinical outcomes. However, the clinical utility of MR perfusion for guiding therapy or affecting outcome has not been documented by large prospective trials; therefore, it is considered an optional element of a CSC.

MR angiography (MRA) is an effective and noninvasive technique for visualizing abnormalities of the extracranial and the intracranial cerebral circulation. The overall sensitivity and specificity of MRA for extracranial carotid disease is 82% to 86% and 98%, respectively. MRA is more sensitive than U/S alone for diagnosing high-grade extracranial carotid stenosis. Its accuracy for detecting significant high-grade extracranial vascular disease in some cases (particularly elliptic centroid contrast MRA) approaches that of catheter-based digital angiography (CA), considered to be the “gold standard,” with a sensitivity of 97% and a specificity of 95% (grade IA). The use of intravenously injected contrast
Material has further increased the accuracy, spatial resolution, and reproducibility of MRA. The accuracy and reproducibility of MRA for detecting intracranial stenoses is less. The time frame for doing MRA is similar to that for a brain MRI.

MRA can also be useful for detecting intracranial aneurysms. The accuracy of this technique depends on the size of the aneurysm, the field strength of the magnet, and the type of MRA sequence used. For intracranial aneurysms >5 mm, nonenhanced 3D time-of-flight MRA performed on a 1.5-T system has an accuracy of >85% relative to CA, although accuracy approaches 100% with increasing aneurysm size (grade IIB).

MR venography (MRV) is a safe, rapid, and noninvasive technique to diagnose cerebral venous thrombosis (CVT). A positive MRV can eliminate the need for invasive cerebral angiography in many cases of CVT, although false positives can occur. Software for performing MRV is available on all current scanner systems. Because of the ability of MRV to noninvasively diagnose CVT and the wide availability of MRV, it is a recommended technique for a CSC (grade IIB).

Catheter Angiography (Grade IA)
Digital subtraction angiography (DSA) represents the gold standard for the detection and characterization of cerebral aneurysms, arteriovenous malformations (AVMs), and arteriovenous fistulae (AVFs), and for measuring the exact degree of stenosis in extracranial and intracranial arteries (grade IA). It is the procedure of choice for evaluating the degree of stenosis in extracranial and intracranial arteries and the ability to detect minute amounts of contrast material. In general, CTA has sensitivities and specificities of 80% to 100% for detecting high-grade extracranial lesions. CTA cannot provide the same detailed cerebral hemodynamic data provided by CA, nor can it accurately image small cerebral vessels. However, because of the significant flexibility and accuracy of CTA, particularly for patients who cannot undergo an MRA or a conventional cerebral angiogram, and its noninvasive nature, it is a recommended element for a CSC (grade IA). It is possible that in the near future, CTA might replace CA for many indications.

Extracranial Ultrasonography (Grade IA)
Carotid U/S is relatively inexpensive, very safe, and can be used to noninvasively screen for disease and follow known disease in the extracranial carotid and vertebral arteries. It can be used in patients unable to receive contrast dyes or in whom an MRA is contraindicated (pacemaker, metal implants, etc). The sensitivity and specificity of carotid U/S can be as high as 85% to 90% for hemodynamically significant lesions at the carotid bifurcation, although it is less sensitive for disease in the vertebral arteries. Because of its ease of use and accuracy, it is recommended that a CSC have extracranial U/S and demonstrate acceptable proficiency using guidelines established by the Intersocietal Committee for the Accreditation of Vascular Laboratories (ICAVL) or a similar credentialing organization.

Transcranial Doppler (Grade IA)
TCD is a safe, noninvasive, and low-cost technique for imaging the large intracranial vessels at the skull base. It is used in patients with acute cerebral ischemia for the detection of intracranial stenosis and occlusions and for the detection of vasospasm in patients with neurological deterioration after subarachnoid hemorrhage (SAH). For the detection of vasospasm, TCD has a sensitivity of 80% and a specificity of 95% compared with CA. Other studies have shown TCD to be useful for monitoring recanalization after thrombolytic therapy. Based on its accuracy and importance in monitoring patients with SAH, TCD is a recommended element of a CSC. As with carotid U/S, the TCD laboratory should track their results and seek certification from ICAVL or a similar organization.

Transcatheter and Transesophageal Echocardiography (Grade IA)
Because a significant percentage of strokes are of cardioembolic origin, cardiac imaging is an important test in most stroke patients. Practice guidelines support cardiac imaging in cases of transient ischemic attack and stroke. Transthoracic echocardiography (TTE) is a routine test used to image the heart for the presence of clots, valvular abnormalities, and the determination of left ventricular function and wall motion abnormalities. Transesophageal echocardiography (TEE) is a highly sensitive test for detecting several cardiac and aortic lesions that may cause ischemic strokes, including thrombi in the left atrium, masses on the mitral and aortic valves, a patent foramen ovale, intral-atrial septal aneurysm, and atherothrombotic lesions in the aortic arch. Numerous studies have proven the increased sensitivity of TEE compared with TTE in patients with ischemic strokes. TEE and TEE must be performed and interpreted by technicians and cardiologists with training in these techniques.
Tests of Cerebral Blood Flow and Metabolism

There are a variety of methodologies currently available that assess cerebral blood flow, including MR perfusion, CT perfusion, single-photon emission CT, positron emission tomography (PET), and xenon CT. PET provides data about cerebral blood flow, brain metabolism, and degree of ischemia. It may be useful in some cases for guiding acute therapy (grade IIIC). However, sophisticated hardware is required to detect and measure these isotopes, and their production requires expensive infrastructure. All of these tests are non-invasive. There is no compelling data that these tests alter management or outcomes in most patients. Some cannot be done on an emergent basis. They may be most useful at the present time as part of research protocols.

Diagnostic Radiology Personnel

A CSC must have physicians available to evaluate imaging studies 24/7. Although it is preferable that the attending physician be a fellowship-trained neuroradiologist, very few institutions have an in-house fellowship-trained neuroradiologist on a 24/7 basis, although many have a general diagnostic radiologist available in-house 24/7. For urgent neuroimaging studies, physicians experienced in interpreting head CT and brain MRI studies must be available to read these scans within 20 minutes of their completion. The proliferation of telecommunications systems for the rapid assessment of studies, physicians experienced in interpreting head CT and brain MRI studies must be available to read these scans within 20 minutes of their completion. The proliferation of telecommunications systems for the rapid assessment of diagnostic images makes quite feasible the requirement that an emergency CT scan or MRI is evaluated by a neuroradiologist, general diagnostic radiologist, or other suitably trained physician in a variety of care settings within 20 minutes of scan acquisition.

Because of the need for the performance of a CT scan within 25 minutes, there must be an in-house technologist capable of performing a CT scan and any CT-based studies. The American Society of Radiological Technologists, American Registry of Radiological Technologists, and the Joint Review Committee on Education in Radiologic Technology all have requirements for the training, testing, and certification of technologists performing all types of imaging studies. A CSC must have ≥1 certified radiology technologist trained in CT techniques in-house on a 24/7 basis.

The requirement that a CSC will perform MRI studies on a 24/7 basis means that a qualified MR technologist must be available (but not necessarily in-house) on a 24/7 basis. The technologist may take calls from home as long as he/she can be at the hospital within 1 hour of being paged. A similar requirement applies to technologists and technicians needed to perform a cerebral angiogram. U/S and various cerebral perfusion studies are commonly elective, and the availability of technologists to perform them will vary among institutions.

Endovascular Therapy: Procedures and Personnel

Endovascular techniques and devices are being used with increasing frequency for the treatment of a variety of cerebrovascular diseases. These include ablation of cerebral aneurysms, angioplasty and stenting of occlusive lesions, intracranial angioplasty for vasospasm, intra-arterial (IA) thrombolysis for acute stroke, and embolization of AVMs and AVFs.

The endovascular ablation of aneurysms is a safe and effective alternative to surgical clipping in selected patients (grade IA). Published multicenter trial results and guidelines support the use of endovascular therapy in such patients. A multinational trial of endovascular treatment using the Guglielmi detachable coil (GDC) versus surgical clipping of ruptured intracranial aneurysms found a 7% absolute risk reduction of death or dependency in patients treated with the GDC compared with surgery. These results may not be extrapolated to all patients with all types of aneurysms. Complete aneurysm ablation may be less common with endovascular coiling than with clipping, and there may be a higher rate of early rebleeding. The long-term durability of endovascular ablation versus surgical clipping remains unclear. Some aneurysms appear to be better treated with an endovascular approach and others with surgical therapy. Therefore, a CSC is required to have the capability to perform microsurgical neurovascular clipping and neuroendovascular coiling.

Vasospasm is a frequent and deadly complication of an SAH. Medical management such as hemodynamic therapy often fails to reverse the clinical effects of the vasospasm. Catheter-directed intracerebral IA infusion of vasodilators is an important therapeutic option used routinely in some cases of vasospasm with mixed results (grade IIIC). Intracranial angioplasty for vasospasm has a success rate of >90% in correcting the angiographically visible vasospasm, with clinical improvement in 60% to 80% of patients (grade IIIC) and a complication rate of 2% to 4%. Although angioplasty for vasospasm has not been subjected to rigorous clinical study, it is considered very effective and is a standard therapy for severe vasospasm. Because the other therapeutic options for symptomatic vasospasm are limited and often ineffective, the ability to perform intracranial angioplasty or IA infusions of vasodilators is recommended for a CSC. If a CSC is temporarily unable to offer this therapy, it is recommended that protocols be developed for the rapid transfer of patients needing these treatments to a nearby facility that does offer this therapy.

IA thrombolysis involves the use of advanced angiographic techniques for the placement of a microcatheter into a cerebral vessel for the infusion of a thrombolytic drug. IA thrombolytics have increased efficacy compared with intravenous lytics for dissolving thrombi within the large arteries at the skull base, although it carries a 10% to 18% risk of symptomatic intracerebral hemorrhage (ICH) in some cases. The use of IA lytic agents might extend the time window for therapy beyond the 3-hour requirement for intravenous thrombolysis. One prospective, randomized trial of IA pro-urokinase showed a 15% absolute increase in good neurologic outcomes and a 10% rate of symptomatic ICH. Other smaller case series have also found significant benefits for IA thrombolysis in stroke patients with large artery occlusions.
commonly used at many medical centers, and it is recommended in the current AHA Advanced Cardiac Life Support handbook.\textsuperscript{120-122} Based on all of these factors and the consensus of BAC, IA lytics are considered a recommended component of a CSC (grade IIB). Complication rates should be monitored closely. Mechanical thrombectomy techniques for the cerebral circulation are also being developed that use a variety of devices such as microcatheters, snares, clot retrievers, and balloons\textsuperscript{123-126} (grade VC). A clot retrieval device recently received FDA approval, although clinical experience is limited.\textsuperscript{127} Intrinsus lytic agents may also be efficacious in treating selected cases of CVT, although this therapy has not been studied in a rigorous manner\textsuperscript{128-132} (grade VC).

Carotid angioplasty and stenting (CAS) may be an option for the treatment of selected patients with symptomatic or asymptomatic carotid artery stenosis. Over the past 10 years, the technical success rate for CAS has risen to $\geq 97\%$, and the complication rates have fallen.\textsuperscript{133,134} However, there is a paucity of data from prospective, randomized studies comparing the efficacy and safety of CAS to CEA or to best current medical therapy. One randomized study of 220 patients with symptomatic carotid artery stenosis found the 1-year stroke and vascular death rate to be higher in the stent group versus CEA group (10.4\% versus 4.6\%), although these differences were not statistically significant.\textsuperscript{135} The Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) compared endarterectomy with angioplasty (25\% of patients also received a stent) in patients with carotid or vertebral artery stenosis.\textsuperscript{136} Overall, there were no significant differences in major outcomes such as stroke and death. Data from a large unrandomized registry found the 1-year stroke and death rate to be 11\% in the stent group, about half of whom had asymptomatic lesions.\textsuperscript{137} A study of high surgical-risk patients found the 30-day complication rate of carotid stenting to be half that of CEA when using a distal protection device (6\% versus 12\%).\textsuperscript{138}

There is general agreement that CAS may be an acceptable treatment option in patients thought to be at high risk for a CEA (ie, restenosis after CEA, radiation fibrosis, fibromuscular dysplasia, surgically inaccessible stenosis, contralateral carotid disease, and significant cardiac or pulmonary disease).\textsuperscript{139,140} Stenting may also be considered in patients with arterial dissection that is unresponsive to medical therapy or in whom treatment with anticoagulation is contraindicated.\textsuperscript{141,142} Based on all of this information, stenting of extracranial carotid arteries for atherothrombotic disease is grade IIB and is considered an optional element of a CSC (see below). The National Institutes of Health (NIH)-sponsored multicenter CREST (Carotid Revascularization: Endarterectomy versus Stenting) trial that is now under way will hopefully determine the relative safety and efficacy of CAS compared with CEA in patients with average surgical risk and symptomatic extracranial carotid stenosis.\textsuperscript{143}

BAC recommends that for patients with average surgical risk, such as those who would have qualified for enrollment in the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Asymptomatic Carotid Atherosclerosis Study (ACAS), CAS should be performed as part of a randomized clinical trial such as CREST or under a local institutional review board–approved investigational program. CAS placement should only be performed by an individual or team with training and expertise in cerebral angiography, cerebrovascular pathophysiology, hemodynamics, and neurovascular interventions.\textsuperscript{144,145}

Angioplasty and stenting of stenotic lesions in the intracranial circulation (including vertebral–basilar territory) is another area of great interest because of the poor outcome in patients who fail medical therapy.\textsuperscript{146} However, there is a paucity of data from randomized controlled trials to properly evaluate this treatment approach.\textsuperscript{147} Some studies have found 30-day complications rates of 5\% to 30\% and 12-month stroke and death rates of 28\% to 40\% for intracranial angioplasty/stenting.\textsuperscript{148-151} In comparison, the Warfarin–Aspirin Symptomatic Intracranial Disease (WASID) study found an annual stroke rate of 15\% for patients with intracranial symptomatic lesions with $>50\%$ stenosis.\textsuperscript{152}

The Stenting of Symptomatic Lesions of the Vertebral and Intracranial Arteries (SSYLVIA) trial reported a stroke and death rate of 6.6\% in 30 days and a 12-month stroke and death rate of 13.2\%.\textsuperscript{153} The SSYLVIA trial resulted in FDA approval for a specific angioplasty balloon and stent for intracranial atherosclerotic stenosis. The 2 largest reported series of long-term stroke prevention for intracranial angioplasty or stenting demonstrated very low long-term stroke/death rates of $<3.5\%$, with $>300$ patient years of follow-up in 1 series and 70 patient years in the other.\textsuperscript{151,154} Because of the lack of data from large, prospective randomized trials, extracranial and intracranial angioplasty/stenting for cerebrovascular disease is considered an optional component for a CSC, although there are selected cases in which such techniques may be of value (grade IVC). If a center does offer this procedure, it is recommended that cases be entered into a registry to track outcomes. It is recommended that if a CSC does not offer extracranial and intracranial angioplasty/stenting, it has available a referral arrangement to send selected patients to another facility that does offer these interventions.

Some AVMs cannot be easily treated with conventional surgery alone. Preoperative embolization may decrease the flow sufficiently so that surgical resection is possible.\textsuperscript{155,156} In other cases, embolization may reduce the size of the AVM sufficiently to allow focused irradiation.\textsuperscript{157,158} Rarely, embolization alone may be curative.\textsuperscript{159} Some AVFs are treated solely with endovascular ablation techniques, whereas others might be treated with surgery alone. Occasionally, a combination of methods must be used.\textsuperscript{160,161} These techniques have not been studied in rigorous, randomized clinical trials (grade IIC).\textsuperscript{162,163}

A neuroendovascular specialist (eg, endovascular surgical neuroradiologist) is recommended as a necessary component of a CSC. An individual with such expertise is capable of performing extracranial and intracranial angioplasty and stenting for atherosclerosis or vasospasm as well as performing emergency catheter-directed IA stroke therapy. The endovascular treatment of patients with cerebral aneurysms, AVMs, and AVFs requires these specialized skills.\textsuperscript{166} These neuroendovascular procedures are technically and cognitively demanding and should only be performed by physicians with
formal and specific training (or equivalent experience) in neurointerventional therapy, working in coordination with a multidisciplinary team. Specific pathways and guidelines for the training and credentialing of a neuroendovascular specialist and for carotid stenting have been published. In all cases, BAC recommends that the neuroendovascular specialists receive specific formal training and accrue significant experience in a procedure because past studies have shown that more experience and an increasing number of procedures reduce complication rates.

It is recommended that a multidisciplinary team evaluate patients before and after some of the endovascular procedures outlined above to discuss treatment options and assess for complications during and after the intervention. This is important because of the emerging and changing role of endovascular approaches to disease treatment but should also be applied to some vascular surgical procedures. Other vital team members include nurses and technologists with training in endovascular procedures. A registry should be established to track treatments, outcomes, and complications. Yearly comparisons should be made between the CSC complication rate and rates reported from national surveys and guidelines.

For all of the endovascular and surgical procedures performed at a CSC, the number, indications, and outcomes should be recorded and available for review. A quality assurance process should confirm that procedures and therapies are performed for appropriate indications, with rates of success and complications that meet acceptable standards. The committee should define a list of appropriate indicators that would trigger automatic chart review. When case reviews find significant deviations in the standards of care, the committee should recommend corrective action through appropriate methods.

**Neurosurgery and Vascular Surgery**

Some patients with an ICH, SAH, large ischemic stroke, or significant carotid disease will require surgical interventions (Table 3). Operative procedures may include evacuation of intracerebral hematoma, clipping of an intracranial aneurysm, excision of an AVM, placement of a ventriculostomy for drainage of cerebrospinal fluid, a CEA, decompressive craniotomy, and other procedures. The medical evidence in support of these recommendations varies between levels IIB and VC depending on the specific clinical scenario, especially in the case of ICH. Nonetheless, there are several surgical procedures important for the management of stroke patients that only a neurosurgeon can perform such as insertion of a ventriculostomy, clipping of an intracranial aneurysm, excision of an AVM, or removal of an intracerebral hematoma. Therefore, neurosurgical expertise must be available in a CSC on a 24/7 basis. The attending neurosurgeons at a CSC should have expertise and experience in cerebrovascular surgery. At all times, there must be personnel in-house (or able to be at the hospital within 30 minutes) who are capable of performing emergent neurosurgical procedures and treating life-threatening intracranial conditions such as increased intracranial pressure, mass effect from a hemorrhage, etc. Such personnel may include residents or fellows in an approved neurosurgery residency training program. Such trainees must have attending-level back-up, available on a 24/7 basis, by a board-eligible or board-certified neurosurgeon. Written neurosurgical call schedules must be available in the ED and hospital wards of a CSC.

A CSC must have individuals with expertise and experience in microsurgery for aneurysm clipping and surgical excision of AVMs. A study of in-hospital deaths after craniotomies performed for unruptured aneurysms between 1987 and 1993 in New York state hospitals revealed a 53% decrease in mortality rate in the 21 hospitals in which ≥10 craniotomies per year were performed, compared with the 89 hospitals in which ≤10 craniotomies per year were performed (5.3% versus 11.2% mortality rate, respectively.) The range for mortality and morbidity rates for surgical clipping of unruptured intracranial aneurysms is quite broad, varying from 0% to 7% for death, and 4% to 15.3% for complications. A meta-analysis of 2460 patients reported a mortality rate of 2.6% and a morbidity rate of 10.9%. An international study of clipping of unruptured aneurysms reports a 1-year mortality of 3.2%, a 5.8% rate of moderate or severe disability, and a 6% rate of isolated cognitive impairment. For patients with SAH attributable to ruptured intracranial aneurysms, hospital volume is also strongly associated with outcomes. A study in New York state found a 43% reduction in mortality in hospitals that operated on >30 SAH/IA patients per year. Another study found that hospitals that cared for ≥21 patients per year with aneurysmal SAH had a significantly lower mortality rate (32% versus 49%) and reduced rate of adverse outcomes (56% versus 76%) compared with hospitals with lower volumes. A recent study of 16,399 hospitalizations for SAH in 18 states found that hospitals caring for ≥19 patients per year with SAH had reduced mortality compared with lower volume centers.

Another recent study based on data from 1995 to 1999 found that hospitals with very low patient volumes for cerebral aneurysm clipping had higher mortality rates than very high-volume hospitals for emergency and elective surgeries. Based on these data, it is recommended that for an institution to be considered a CSC, the institution should care for ≥20 SAH patients per year and should accomplish ≥10 craniotomies per year for aneurysm clipping (grade IA). This does not preclude lower-volume centers from having excellent outcomes, nor does it guarantee that high-volume centers will achieve excellent results. Each center should monitor its perioperative complication rates and overall outcomes for comparison with national benchmarks after correcting for various comorbidities. Each neurosurgeon should participate in ≥10 such cases per year. The perioperative mortality rate for aneurysm clipping at a CSC should be documented, reviewed, and compared with published outcomes. For the treatment of AVMs, individual expertise is of paramount importance in treating these complex lesions. The CSC should have the capability and expertise to provide the full spectrum of treatment options required for the treatment of AVMs, including microsurgical excision, endovascular embolization, and stereotactic radiosurgery.
CEA can reduce the risk of stroke in patients with symptomatic and asymptomatic carotid artery stenosis (grade I A). A CEA is typically performed by a vascular surgeon or a neurosurgeon. Documentation of expertise in this operation is critical to ensuring its efficacy. Published recommendations for perioperative complication rates for CEA should be used as benchmarks (Table 4). Results of CSC neurosurgeons and vascular surgeons should be audited on a yearly basis, and the results of a rolling average >3 years should be compared with published outcome and complication rates.

Revascularization procedures and microvascular techniques are important options for the treatment of some ischemic disorders, and in the management of complex intracranial aneurysms. A large, prospective, randomized study of EC/IC by-pass found that this surgery was not of benefit for the management of carotid occlusion/stenosis, or middle cerebral artery occlusion/stenosis (grade I A). Other neurological procedures may have benefit in the management of select patients. For example, microsurgical bypass procedures are an important treatment option for a select but diverse group of other disorders, including moyamoya disease, aneurysms requiring sacrifice of the parent vessel, and tumors needing vessel occlusion (grade IV C). There has been renewed interest in these procedures for patients with symptomatic carotid occlusion. Recent studies have indicated that a select group of patients with carotid occlusion in whom there is a documented alteration of cerebrovascular reserve, such as shown by an increase in the oxygen extraction fraction, have an increased risk of subsequent stroke. An NIH-sponsored multicenter study is currently underway to determine if superficial temporal to middle cerebral artery bypass is effective in reducing the risk of stroke in this select group of patients. There has been renewed interest in these procedures for patients with symptomatic carotid occlusion. Recent studies have indicated that a select group of patients with carotid occlusion in whom there is a documented alteration of cerebrovascular reserve, such as shown by an increase in the oxygen extraction fraction, have an increased risk of subsequent stroke. An NIH-sponsored multicenter study is currently underway to determine if superficial temporal to middle cerebral artery bypass is effective in reducing the risk of stroke in this select group of patients.

Revascularization procedures and microvascular techniques are important options for the treatment of some ischemic disorders, and in the management of complex intracranial aneurysms. A large, prospective, randomized study of EC/IC by-pass found that this surgery was not of benefit for the management of carotid occlusion/stenosis, or middle cerebral artery occlusion/stenosis (grade I A). Other neurological procedures may have benefit in the management of select patients. For example, microsurgical bypass procedures are an important treatment option for a select but diverse group of other disorders, including moyamoya disease, aneurysms requiring sacrifice of the parent vessel, and tumors needing vessel occlusion (grade IV C). There has been renewed interest in these procedures for patients with symptomatic carotid occlusion. Recent studies have indicated that a select group of patients with carotid occlusion in whom there is a documented alteration of cerebrovascular reserve, such as shown by an increase in the oxygen extraction fraction, have an increased risk of subsequent stroke. An NIH-sponsored multicenter study is currently underway to determine if superficial temporal to middle cerebral artery bypass is effective in reducing the risk of stroke in this select group of patients.

Recent studies have indicated that a select group of patients with carotid occlusion in whom there is a documented alteration of cerebrovascular reserve, such as shown by an increase in the oxygen extraction fraction, have an increased risk of subsequent stroke. An NIH-sponsored multicenter study is currently underway to determine if superficial temporal to middle cerebral artery bypass is effective in reducing the risk of stroke in this select group of patients.

**TABLE 4. Complication Rates for CEA**

<table>
<thead>
<tr>
<th></th>
<th>Asymptomatic</th>
<th>Symptomatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perioperative mortality*</td>
<td>&lt;0.2%</td>
<td>&lt;0.7%</td>
</tr>
<tr>
<td>Perioperative stroke and death*</td>
<td>&lt;3%</td>
<td>&lt;6%</td>
</tr>
</tbody>
</table>

*Perioperative refers to within 30 days of surgery (see text for references).

**EMS, ED, Referral, and Triage**

Integration of acute stroke care begins with the EMS system and extends to the ED. Many of these components were reviewed in the PSC publication. Written care protocols for acute stroke patients should be available to EMS and ED personnel. Such protocols should be reviewed and revised at least annually. EMS areas that should be included in such protocols include (1) rapid, efficient patient assessment and triage; (2) prehospital EMS communication with hospital staff; and (3) medical stabilization en route. Systems should be in place to allow for rapid communication between EMS and ED personnel during the transportation of acute stroke patients. The ED should have well-defined and -documented procedures for calling the acute stroke team, including a call schedule. The ED should have a door-to-needle time of ≤60 minutes for the administration of intravenous tissue plasminogen activator (tPA) to stroke patients. The EMS and ED staff should meet and review patient care issues with the CSC staff at least twice per year. At least 2 specific assessment criteria and benchmarks related to acute stroke care should be defined, measured, and reviewed annually. It is recommended that the EMS and ED physicians, nurses, and paramedics attend ≥2 in-service programs (or equivalent educational program) annually that focus on acute stroke care.

The CSC should be viewed as a community and regional resource in the management of stroke patients. EMS and ED personnel, along with members of the stroke team, should play an active role in the triage of acute stroke patients. This might include advice about diagnostic procedures, acute therapies, and referral to an appropriate facility if transfer is required or requested. For example, personnel at a CSC should be available to health care personnel at other hospitals and provide them with guidance and recommendations about the diagnosis and treatment of specific patients. In an emergency setting, such guidance might also include the review of radiologic studies via teleradiology techniques as well as advice about the use of acute therapies such as tPA. A CSC might also coordinate acute care within a geographic region to ensure that patients are transferred appropriately in a timely manner to the facility best suited to care for them. Several examples exist of successful regional acute triage systems for stroke patients. Whenever such communications occur, CSC personnel should not be legally liable, assuming that they provide prudent advice that is consistent with community medical standards.

**Stroke Unit and ICU**

The PSC recommendations include a discussion about the importance of a stroke unit if patients are going to be admitted to the hospital (grade IA). More recent studies have generated additional data supporting the efficacy and cost-effectiveness of stroke units. A recent study found that stroke patients cared for in a stroke unit with continuous cardiac telemetry monitoring were more likely to have significant cardiac arrhythmias detected compared with stroke unit patients who did not have such monitoring. This observation is shared by many vascular neurologists. There-
fore, we recommend that a stroke unit include continuous cardiac and respiratory monitoring when deemed clinically appropriate.

A CSC must have a full ICU because some patients at a CSC (ie, those with large ICHs or SAHs) will require the services of a typical ICU (ie, intubation, ventilator support, peripheral artery and pulmonary artery catheters, ventriculostomies, and use of parenteral vasoactive medications; Table 3). A dedicated neurosciences ICU, although desirable, is not required. The stroke unit may be part of the ICU, although this may not be an efficient use of ICU beds and nursing resources in some hospitals because many ischemic stroke patients do not require the costly infrastructure of an ICU.

The ICU in a CSC should be staffed by physicians with training in cerebrovascular disease and critical care, although they may be different persons. Training in cerebrovascular disease has been defined previously. The critical care physicians must have completed an accredited critical care fellowship program. The ICU director should also have ≥8 hours per year of CME training (or equivalent educational activities) related to cerebrovascular disease. Formal training as a neurointensivist, although preferred, is not a requirement. Coverage by attending physicians or residents with expertise in cerebrovascular disease and critical care must be available 24/7 with a written call schedule. Such coverage may consist of a team approach, with some members from critical care medicine or anesthesiology and others from neurosurgery or neurology.

The nurse:patient ratio in an ICU caring for critically ill stroke patients should be 1:1 or 1:2. It is preferred (but not required) that nurses caring for neuroscience patients in the ICU be board certified in neuroscience nursing. The ICU nursing staff must be trained to assess neurologic function and to deal with several aspects of neurocritical care, including (1) function of ventriculostomy and external ventricular drainage apparatus, (2) treatment of increased intracranial pressure, (3) care of patients with ICH and SAH, (4) care of patients after thrombolytic therapy, (5) treatment of blood pressure abnormalities with parenteral vasoactive agents, (6) management of intubated/ventilated patients, and (7) detailed neurologic assessments and scales (ie, NIH Stroke Scale and Glasgow Coma Scale). Such training can be documented by attendance at in-service sessions, participation in regional or national courses, and other modalities as established by the CSC staff and hospital administration. It is recommended that nurses in the ICU caring for stroke patients receive ≥10 hours per year of CEU credit (or other educational programs) in areas related to cerebrovascular disease.

All stroke patients should be fully evaluated to determine the etiology of their stroke, which is vital for planning their treatment and deciding on approaches for secondary prevention. While the stroke patient is hospitalized, steps should be taken to reduce the risk of peristroke complications such as cerebral edema, aspiration pneumonia, infection, myocardial infarction, and deep venous thrombosis (DVT). A multidisciplinary care pathway is very useful to ensure proper diagnostic and preventive measures are taken in all patients. Medical and surgical therapies should be initiated to prevent secondary strokes and other vascular events. Frequent communications between and among the care team, the patient, and their family will alleviate anxiety and improve planning for poststroke care.

Rehabilitation and Poststroke Care

Rehabilitation after a stroke is a key element for patients. There are 6 areas of focus for poststroke rehabilitation: (1) training for maximum recovery, (2) prevent and treat comorbid conditions, (3) enhance psychosocial coping, (4) promote integration into the community, (5) prevent recurrent strokes and other vascular events, and (6) enhance quality of life. Rehabilitation of stroke survivors should begin as soon as possible. Published studies have demonstrated that organized multidisciplinary stroke rehabilitation reduces death, death or disability, and death or institutionalization (grade IA). Mobilization of the stroke survivor and resumption of self-care activities should occur as soon as medically feasible. Rehabilitation may increase the stroke patient’s quality of life and reduce the financial and physical burden on society (grade IA). In addition to inpatient rehabilitation, outpatient rehabilitation programs can improve outcomes and prevent deterioration (grade IIb).

Rehabilitation services should be directed by a physician with board certification in physical medicine and rehabilitation (ie, physiatrist) or by other properly trained individuals (ie, neurologist experienced in stroke rehabilitation or other physicians or PhDs with fellowship training in rehabilitation). All therapists, social workers, and nurse case managers must meet requirements for state licensure, and have ≥1 year of experience in the treatment of stroke survivors. The physical therapists, speech therapists, and social workers must complete a master’s degree, whereas the occupational therapists and nurse case managers must complete at least a bachelor’s degree. The nurse case managers and social workers must have adequate knowledge of inpatient rehabilitation facilities and community resources in their geographic regions.

A CSC should have physical, occupational, and speech therapists on staff or readily available by consultation for patient assessment and therapy during the acute hospitalization. Consults for physical medicine and rehabilitation, physical therapy, occupational therapy, and speech therapy should be requested and completed (when deemed medically necessary) usually within 24 hours of admission so that medical and therapeutic evaluations may begin as soon as the stroke survivor is medically stable. If the CSC does not have inpatient rehabilitation facilities on site, they should have documented referral protocols and a working knowledge of nearby facilities.

Other important measures include steps to prevent and treat medical complications of stroke such as aspiration pneumonia and other infections, cerebral edema/herniation, DVT, pressure sores, and contractures. Poststroke care should include assessment and treatment (when possible) of cognitive decline, depression, and social implications of stroke. These various therapies have been reviewed in other recent publications and are not reiterated here.

Education

Educational programs are deemed a very important component of a CSC. Such programs can be divided into profes-
sional and public efforts. For professional programs, it is recommended that the CSC staff prepare and present ≥2 educational courses per year aimed at health care professionals within or outside of the CSC.

Public education is a vital component that can improve acute care by decreasing delay times for presentation (grade IA). Public education about stroke risk factors may also facilitate improved therapy (grade IIB). Other public education programs related to vascular disease risk factors may also be useful, although results of randomized trials have been mixed. It is recommended that a CSC sponsor at least 2 public educational activities each year that focus on some aspect of stroke. These could include lectures, screening for stroke risk factors, health fairs, and similar events. Such events could be advertised and marketed to high-risk groups in such areas as those with a high minority population, areas with poor access to health care, and other underserved populations.

A fellowship in cerebrovascular disease accomplishes several important goals, such as providing additional training and experience and preparing physicians for a career that focuses on cerebrovascular disease. The Accreditation Council for Graduate Medical Education (ACGME) has recently approved the formation of an officially recognized fellowship program in vascular neurology. A CSC does not need to have a fellowship program to provide excellent patient care. It is recommended that a CSC that chooses to offer a fellowship in cerebrovascular disease follow the guidelines of the ACGME and work closely with the American Academy of Neurology in developing a training curriculum.

Research
Research programs are an important component of academic medical centers, and some community hospitals are also becoming involved in clinical research trials. Past studies have documented that patients involved in clinical research have better outcomes than patients not involved in such research (grade III). However, a hospital can clearly provide excellent care as a CSC and not be involved in any research. Therefore, research is considered an optional component of a CSC.

Other
A stroke registry is an important element of a CSC. A stroke registry is a systematic collection of data that deals with stroke care, risk factors, outcomes, and related issues. Such a registry is important for tracking outcomes and defining areas in need of improvement and is included in the recommendations for a PSC. It is recommended that a CSC have a stroke registry or another similar data collection tool (grade IIIC). A pilot project for developing a national acute stroke registry is currently under way.

A stroke clinic could have a multidisciplinary faculty that would address several components of stroke care, including prevention, rehabilitation, medical complications, and social issues. It is recognized that some CSC facilities may not have the space for a multidisciplinary stroke clinic or that other logistical factors could limit the formation of such a clinic. In addition, such care could be provided in another clinic setting such as a multidisciplinary vascular clinic. For this reason, the stroke clinic is an optional component of a CSC.

An air ambulance is an important transportation option for some hospitals because of specific geographic considerations. In large cities, such a service may reduce transportation times because of high traffic volume on congested highways. In rural locations, an air ambulance may be a vital service offered by a CSC to transport acute stroke patients from outlying facilities. Studies have shown that such a service can reduce treatment times for thrombolytic therapy in acute stroke (grade IIB). However, a CSC in some urban settings can certainly function well without such a service. Therefore, an air ambulance is an important but optional feature of a CSC, depending largely on local transportation, referral, and geographic factors.

Quality assurance and improvement are important processes for maintaining and enhancing the quality of health care at any type of stroke center. This is particularly true in a CSC, in which very ill patients with complex diseases are sometimes treated with potentially dangerous medications and procedures. Because of the serious consequences of stroke and its related complications, as well as the complexity of surgical and endovascular procedures performed at a CSC, it is essential that outcomes be monitored. A multidisciplinary institutional quality assurance committee should meet on a regular basis to monitor quality benchmarks and review complications. This committee should include members who participate in the care of stroke patients as well as others who are not participating directly in such care but could provide insight into overall patient care. The goal of this quality assurance program is quality improvement, correction of errors, and systems improvement.

In addition to monitoring the outcomes of procedures performed at a CSC, the quality assurance committee should also monitor the overall care of patients. A database or registry should be established that allows for tracking of parameters such as length of stay, treatments received, discharge destination and status, incidence of complications (such as aspiration pneumonia, urinary tract infection, and DVT), and discharge medications. Specific benchmarks and indicators should be set and reviewed on a regular basis (at least annually). There are several multi-institutional or national databases that can be used to establish appropriate benchmarks.

Discussion
The diagnosis and treatment of some patients with complex types of stroke or with severe deficits and multiorgan problems may require more resources and a higher intensity of care than is offered in many hospitals and in most PSCs. Such patients often require and may benefit from advanced diagnostic and treatment procedures directed by specialty-trained physicians and other health care professionals. A CSC would have the staffing, expertise, infrastructure, and programs to meet the needs of these patients and to serve as a resource to the PSCs in the region.

Many of the recommendations outlined above are meant to benefit the types of patients likely to be cared for in a CSC, namely those with hemorrhagic strokes, large ischemic
strokes, strokes of unknown or unusual etiology, and patients with multisystem involvement. Unlike most of the recommendations for a PSC, there is a relative paucity of data proving that some of the components of a CSC change outcomes. However, there are data to support the utility and advantages of most of our recommendations, particularly in the areas of neuroimaging and certain specialized therapeutic procedures. There are emerging data that support the efficacy of other interventions related to neurosurgery and endovascular therapies. As these fields advance, we anticipate the publication of further studies that provide outcomes data for many of these interventions.

The costs for establishing and maintaining a CSC will vary depending on the existing staffing, infrastructure, and programs at a particular hospital. Several of the components of a CSC are quite costly, including an MRI scanner and an angiography suite, each of which can cost in excess of $1 million. Many hospitals that strive to be a CSC already have some of the equipment and infrastructure in place, which would reduce the costs considerably. The hiring of additional personnel (ie, endovascular interven tionsists and neurointensivists) and having staff members on call would also increase the costs, perhaps by $200 000 to $300 000 or more each year. Some of these costs could be offset by hospital billing for some procedures and physician billing for professional services. At this time, data do not exist to project a meaningful or accurate cost-benefit analysis for a CSC. Individual hospitals will have to develop business plans that consider the volume of stroke patients, payor mix, average costs and revenue per case, and future growth plans.

In the current health care environment, there continues to be growth of hospital networks and systems throughout the country. Within such a network or system, one approach to acute stroke care might be to designate some hospitals as PSCs and others as CSCs (Figure). This approach would allow for patients, equipment, and expertise to be concentrated at specific hospitals rather than spread throughout the entire network. This is quite similar to the paradigm used for other complex diseases that require a multidisciplinary team approach such as trauma, cancer, severe burns, and organ transplantation. A recent review documented the effective-
ness of the trauma center network for enhancing treatment and improving outcomes for patients with acute traumatic injuries.266

Is there a specific number of hospitalized stroke patients needed to support the formation of a CSC? Without specific cost-benefit data for a CSC, it is difficult to define specific patient volumes. It might be possible to extrapolate from some of the studies cited above that correlate volumes with outcomes. For example, if a CSC must care for ≥20 patients per year with SAH, and SAH represents ~10% of all stroke cases admitted to a CSC hospital (this number may be increased because of referral bias of very ill patients), then the number of annual stroke admissions should approximate 200. However, there will be significant heterogeneity based on the surrounding population, catchment area, regional resources, referral patterns, local competition, etc.

Medical knowledge and technology are advancing at a rapid rate in many areas. BAC appreciates the fact that new techniques will become available for diagnostic studies, and new approaches will be developed for systemic and endovascular therapies of stroke. These recommendations are meant to be flexible and modifiable as new diagnostic and therapeutic options become available.

In summary, BAC has developed recommendations for CSCs and systems that will serve to guide the development of such centers and ensure that patients with cerebrovascular disease receive timely and effective care. We are hopeful that these recommendations will also assist hospitals and referral networks of PSCs and CSCs so that stroke patients receive care and resources that are most appropriate for their clinical condition. As new data become available, it will be important to modify these recommendations to reflect best practices and current guidelines.

Acknowledgments

The authors wish to thank Nancy Hart, MA, and Sara Fassino for their skillful and dedicated administrative support in producing this manuscript. BAC consists of the following organizations and representatives who have approved publication of this document: American Academy of Neurology (Dr Koroshetz); American Association of Neurological Surgeons (Dr Selman); American Association of Neuroscience Nurses (Mr Shepherd; Ms Rose-DeRenzy); American College of Emergency Physicians (Dr Jagoda); American Stroke Association, a Division of the American Heart Association (Ms Mulligan); National Institute of Neurological Disorders and Stroke Ane (Dr Koroshetz); American Society of Neuroradiology (Dr Connors); American Society of Neuroradiology (Dr Latchaw); Centers for Disease Control and Prevention (Dr Mayberg); American Society of Neurology of the American Heart Association (Dr Connors); American Society of Neurology of the American Heart Association (Ms Magnis); American Society of Interventional and Therapeutic Neuroradiology (Dr Connors); American Society of Neuroradiology (Dr Latchaw); American Stroke Association, a Division of the American Heart Association (Ms Magnis); American Society of Interventional and Therapeutic Neuroradiology (Dr Connors); American Society of Neuroradiology (Dr Latchaw); Centers for Disease Control and Prevention (Dr Crotta); Congress of Neurological Surgeons (Dr Hadley and Cawley); National Association of EMS Physicians (Dr O’Conner); National Stroke Association (Ms Mulligan); National Institute of Neurological Disorders and Stroke (Drs Marler and Walker, Ms Emr, Ms Warren); Physical Medicine and Rehabilitation (Dr Zorowitz); Stroke Belt Consortium (Dr Albers); and Veterans Health Administration (Drs Brass and Booss).

References

Recommendations for Comprehensive Stroke


Recommnedations for Comprehensive Stroke


114. Alberts et al Recommendations for Comprehensive Stroke 1613


### Recommendations for Comprehensive Stroke Management

**Aims:** To provide comprehensive guidelines for the management of acute stroke, focusing on the following areas:

1. **Diagnosis and Evaluation:**
   - **Neuroimaging:** Use of CT or MRI to confirm stroke diagnosis.
   - **Functional Assessment:** Evaluation of motor, sensory, speech, and cognitive functions.

2. **Therapeutic Strategies:**
   - **Acute Ischemic Stroke:** Use of thrombolytics, mechanical thrombectomy, and endovascular techniques.
   - **Intracerebral Hemorrhage:** Treatment strategies including surgical intervention.
   - **Subarachnoid Hemorrhage:** Early surgical clipping or coiling.

3. **Rehabilitation:**
   - Early mobilization and occupational therapy to maximize functional recovery.
   - Cognitive rehabilitation for patients with post-stroke cognitive impairment.

4. **Secondary Prevention:**
   - **Antithrombotic Therapy:** Use of anticoagulants for atrial fibrillation and other indications.
   - **Antiplatelet Therapy:** Use of aspirin and clopidogrel to prevent recurrent stroke.

5. **Special Populations:**
   - **Pediatric Stroke:** Unique aspects of diagnosis and management.
   - **Geriatric Stroke:** Special considerations for elderly patients.

6. **Research and Future Directions:**
   - **Clinical Trials:** Ongoing studies to evaluate new therapeutic strategies.
   - **Epidemiological Studies:** Tracking trends in stroke incidence and outcomes.

**References:**


Recommendations for Comprehensive Stroke Centers. A Consensus Statement From the Brain Attack Coalition